The Motley Fool

Could GlaxoSmithKline and this high-yielding share maximise my profits in a stock market recovery?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images.

If the stock market recovery continues which shares will do best? Right now that’s the big question. I think one way to set oneself up for success if the market rallies from this point on, would be to invest in high-yielding shares like GlaxoSmithKline (LSE: GSK) and Vodafone (LSE: VOD).

Pharma share a big winner in a stock market recovery?

Despite Pfizer winning the race to announce the first effective vaccine for Covid-19, other pharma groups are still working on vaccines. This includes GlaxoSmithKline. GSK is involved with three potential solutions being developed by Sanofi, Medicago and Clover Pharmaceuticals.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

The Sanofi/GSK vaccine has pre-orders from governments including the UK’s. The Pfizer vaccine, even with its claimed 90% effectiveness, still leaves the door open for other jabs. I think there’s still an opportunity for GSK to play its part in rescuing the world from 2020’s nightmare.

Looking longer term though, investors could benefit from the reorganisation of the business. By becoming more focused on pharmaceuticals and spinning out its consumer division, GSK should be able to put more resources into finding blockbuster drugs. This is what AstraZeneca has done well over the last five years or so. Its share price has performed far better than GSK’s as a result.

Lastly, for investors like me who are prepared to wait for GSK to improve, there’s the dividend yield, which is a very juicy 5.5%. 

All in all, I think GlaxoSmithKline could be among the winners if there is a stock market recovery. The shares are cheap and high-yielding, which is what I think investors will be looking for as many growth shares have arguably become too expensive.

The high-yielding share with recovery potential 

Yielding around 7%, I think Vodafone’s shares are another good option for investors. Especially those who want to create an income from dividends. The shares are well down on where they started the year so there’s potential for a major bounce-back if sentiment continues to improve.

The dividend was cut last year, making it more sustainable now, and free cash flow cover also makes the dividend more secure. The group is targeting 2.5 to 3 times net debt-to-cash profits. This also means the dividend is less likely to be cut by management, I feel.

Steps towards the sale of Vodafone’s European tower assets have continued. The telecoms group is targeting an early 2021 IPO for the newly formed Vantage Towers. This will provide cash for 5G which should bring opportunities for the group.

If Vodafone can improve its performance in European markets, for example, through selling more data and better cross-selling of services to customers, then I’d be more confident buying the shares as a long term investment. At the moment though, growth is a little on the low side. This makes the dividend the main attraction of the shares. 

That said, I think the share price could be boosted in the short term by improved investor sentiment and investors looking for high yielding shares. This is making me look more closely at the share and the potential for it to bounce back. 

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic…

And with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be daunting prospect during such unprecedented times.

Fortunately, The Motley Fool is here to help: our UK Chief Investment Officer and his analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global lock-down…

You see, here at The Motley Fool we don’t believe “over-trading” is the right path to financial freedom in retirement; instead, we advocate buying and holding (for AT LEAST three to five years) 15 or more quality companies, with shareholder-focused management teams at the helm.

That’s why we’re sharing the names of all five of these companies in a special investing report that you can download today for FREE. If you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio, and that you can consider building a position in all five right away.

Click here to claim your free copy of this special investing report now!

Andy Ross owns shares in AstraZeneca. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.